Jefferies Group's ALNY Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 16.5K shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $7.54 M, representing 0.04% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in ALNY, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 44.9K shares. Largest reduction occurred in Q1 2025, reducing 31.8K shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Jefferies Group
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2022 | +10,711 | New Buy | 10,711 | $237.65 |
| Q1 2023 | -6,171 | Reduce 57.61% | 4,540 | $200.32 |
| Q2 2023 | +5,367 | Add 118.22% | 9,907 | $189.94 |
| Q3 2023 | -5,129 | Reduce 51.77% | 4,778 | $177.10 |
| Q4 2023 | -4,632 | Reduce 96.94% | 146 | $191.41 |
| Q1 2024 | +1,696 | Add 1161.64% | 1,842 | $149.45 |
| Q2 2024 | +458 | Add 24.86% | 2,300 | $243.00 |
| Q3 2024 | +44,893 | Add 1951.87% | 47,193 | $275.03 |
| Q4 2024 | -47,193 | Sold Out | 47,193 | $0.00 |
| Q1 2025 | +15,347 | New Buy | 15,347 | $270.02 |
| Q2 2025 | -7,005 | Reduce 45.64% | 8,342 | $326.09 |
| Q3 2025 | +8,200 | Add 98.30% | 16,542 | $456.00 |
Jefferies Group's Alnylam Pharmaceuticals Investment FAQs
Jefferies Group first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q4 2022, acquiring 10,711 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Alnylam Pharmaceuticals, Inc. (ALNY) for 12 quarters since Q4 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q3 2024, adding 47,193 shares worth $12.98 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 16,542 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $7.54 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.04% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 47,193 shares, as reported at the end of Q3 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.